Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset

By A. Furlan, Dirk Eyding, G. Albers, Yasir Al-Rawi, K. Lees, H. Rowley, C. Sachara, Mariola Soehngen, S. Warach, W. Hacke. Stroke, 2006

612 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. (2008, background): “Intravenous desmoteplase administered 3 to 9 hours after acute ischaemic stroke in patients selected on the basis of perfusion/diffusion mismatch was associated with a higher rate of reperfusion and better clinical outcome, compared with placebo, in two small randomized clinical trials (RCTs) [404, ”
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (2013, positive): “Two phase II trials of desmoteplase provided encouraging safety and potential efficacy data in penumbral imaging–selected patients 9 hours after stroke onset.(347,349) However, a larger trial revealed no benefit of either of 2 doses of desmoteplase over placebo, possibly because of a higher than pro”